title: Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up.
abstract: We describe the management of subretinal fluid and macular oedema due to colorectal cancer metastasis to the choroid using intravitreal bevacizumab. A patient with grade VI KRAS mutation rectal cancer with metastasis to the lung and cerebellum presented with left eye choroidal metastasis 1 week after being started on the experimental medication KTN3379. After intravitreal bevacizumab administration, the patient had improvement in macular subretinal fluid, but eventually progressed to severe cystoid macular oedema despite monthly intravitreal bevacizumab treatment.
authors: Department of Ophthalmology, Kresge Eye Institute, Detroit, Michigan, USA Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan, USA.
authors: Joseph Daniel
authors: JD
authors: Boss
authors: Kresge Eye Institute, Detroit, Michigan, USA.
authors: Philip
authors: P
authors: Lieu
authors: Kresge Eye Institute, Detroit, Michigan, USA.
authors: Asheesh
authors: A
authors: Tewari
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002528:Cerebellar Neoplasms / Q000556:secondary; D002830:Choroid Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008175:Lung Neoplasms / Q000556:secondary; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D012004:Rectal Neoplasms / Q000473:pathology*; D058471:Subretinal Fluid; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab